Biomedical startup company Biome, founded by Kaunas University of Technology (KTU) researchers, is offering a synthetic bone equivalent used for bone restoration operations in odontology.
The bone equivalent Cell’in, created by Lithuanian researchers, is made from cellulose/hydroxyapatite composite. The analogical products in global market are usually created on the basis of synthetic polymers.
The bone equivalent was created by collaborating groups of researchers at KTU, headed by Professor Jolanta Liesien? (Faculty of Chemical Technology) and Lithuanian University of Health Sciences (LSMU), headed by Professor Gintaras Juodžbalis (Face and Jaw Surgery Clinic).
“The innovative bone equivalent is being created from natural polymer, i.e. cellulose. As in human body there is no cellulase, which helps to decompose cellulose, it degrades very slowly, but after some time is being resorbed. Cellulose is non-cytotoxic, biologically compatible and provides friendly environment for cell absorption and multiplication. The porosity of the implant enables the circulation of nutrients and metabolites”, said Professor Liesien?.
This means that the Cell’in bone implant would stay in place sufficiently long, so as blood vessels network can form and the bone can regrow in the place of a fraction. However, in time it will dissipate without leaving any toxic waste. Moreover, the structure of the artificial bone is completely compatible with the morphology of human bone.
Cell’in implant is an efficient solution in reducing time and price of complex dental implant surgery procedures.
Commercialised by Biome
The invention is being commercialised by a startup Biom?, which was established with the funding from Lithuanian Agency for Science, Innovation and Technology (MITA).
Biome offers an innovative approach towards production of bone equivalents: they are being produced in 3D blocks, which can be cut and shaped by a surgeon into a required size and form. Thus, the implant can fill in the whole fracture in the bone, and its macroporous matrix allows the formation of blood vessel network, which enables the growth of natural bone. After the implant dissipates, its place will be taken by a newly grown natural bone.
Established in 2014, Biome made it to TiE50 TOP Startup 2015, and was recognised as one of 50 most enterprising technology startups in the world. Every year 5 thousands of startups apply for competition from all over the world.
“To the best of our knowledge, we are the first biomedical technologies enterprise from Lithuania, which made it to the list. Now, one of our strategic tasks is finding international partners. For a small and dynamic enterprise, such partnerships are crucial”, said Kristina Lies?, director of Biome.
Although the main Biome’s project is commercialising of cellulose/hydroxyapatite composite bone, the enterprise is developing a number or other projects.
Bone restoration is the second most popular tissue transplant surgery, after bone marrow transplantation. The high demand for bone equivalent, which is used for these surgery operations, is constantly increasing.
The Latest on: Bone restoration
via Google News
The Latest on: Bone restoration
- Current Insights And Recommendations For Tourniquet Use In Foot And Ankle Surgery – Part 2: Potential Complicationson April 22, 2021 at 10:17 am
Due to a lack of concise, standardized guidelines for implementation in foot and ankle surgery, these authors provide a literature review and extrapolate recommendations from existing data existing on ...
- Advanced Implant Dentistry and Oral Restoration Provides Quick and Gentle Tooth Extractions in Cedarhurst, NYon April 22, 2021 at 4:35 am
Drs. Michael Klein and Allon Waltuch of Advanced Implant Dentistry and Oral Restoration provide quick and gentle tooth extractions for those suffering from ...
- An enhanced periosteum structure/function dual mimicking membrane for in-situ restorations of periosteum and bone.on April 21, 2021 at 11:06 pm
Periosteum plays a pivotal role in bone formation and reconstruction. The ideal repair process for critical-size bone defects with periosteum damage is to induce regeneration of periosteum tissue and ...
- Restoration of Rhamphotheca in Birds: A Challenge?on April 18, 2021 at 9:32 pm
The keratinized sheath covering the upper and lower beaks is called rhamphotheca and can be divided into the rhinotheca, or maxillary keratin, and the gnatotheca, or mandibular keratin. The median ...
- Return from sidelining injury involves delicate balanceon April 18, 2021 at 2:30 pm
The injury was classified instead, by several media outlets, as “just a bone bruise.” Just? Relative to a torn ACL, I guess. However, a bone bruise is often a serious injury that will lead to ...
- Recognizing the importance of energy availability in the young athleteon April 14, 2021 at 8:10 am
5,6 It may take up to 1 year or longer to resume menses after EA restoration. Decreased bone density, the result of female athlete triad, may be irreversible, although it can improve with increasing ...
- Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexiaon April 6, 2021 at 10:47 am
Lipocalin 2 (LCN2) has been recently identified as an endogenous regulator of appetite. Here, using pancreatic cancer as a model of cachexia, the authors demonstrate that LCN2 is a critical mediator ...
- Home of the Year: quirky cottages and restored red-bricks among finalistson April 5, 2021 at 7:30 pm
But after the most successful series to date, RTÉ One’s Home of the Year judges Hugh Wallace, Amanda Bone and Suzie McAdam ... it needed a complete restoration as it had no central heating ...
- Mesenchymal stem cells suppress leukemia via macrophage-mediated functional restoration of bone marrow microenvironmenton April 4, 2021 at 5:01 pm
Bone marrow (BM) mesenchymal stem cells (MSCs ... However, whether and how restoration of the impaired BM microenvironment can inhibit leukemia development remain unknown. Using an established ...
- Darlene Soave Joins Cell Source's Board of Directorson April 1, 2021 at 12:00 pm
Cell Source, Inc. (OTC: CLCS) ("Cell Source" or "the Company"), is the world leader in Veto Cell based innovative immunotherapy and today announced that Darlene Soave has been appointed to the Company ...
via Bing News